This article is more than 5 years old. Information may no longer be current.

ProQR posts quarterly net loss

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ProQR Therapeutics reported a second quarter net loss of 11.7 million euros, or 0.30 euros per share, compared with a net loss of 7.4 million euros, or 0.23 euros per share, in the same quarter of 2018, according to a press release.

Research and development costs totaled 9.5 million euros compared with 6 million euros a year ago. The increase was attributed to the initiation of clinical trials of sepofarsen for Leber’s congenital amaurosis 10 and QR421a for Usher syndrome type 2.

General and administrative costs increased from 2.6 million euros in 2018 to 2.9 million euros in 2019.

The company had cash and cash equivalents of 82.5 million euros as of June 30.